IMAGiNe 2.0: The Search for Anti-MAG’s Missing Clue Has Begun

“Will I still be able to walk unassisted in two years?”
It’s one of the questions anti-MAG peripheral neuropathy patients ask their doctors most. And for a long time, no one had a reliable way to answer it.
The IMAGiNe study was created to change that. Since 2016, researchers across multiple countries have been following patients with this rare disease over time, tracking who stays stable, who declines, and why. One clue seemed obvious: most patients carry a specific antibody linked to this disease. But researchers learned that the amount of this antibody in someone’s blood doesn’t reliably predict how sick they’ll get, or how fast. What seemed obvious didn’t hold up.
That’s exactly what inspired the next step. If antibody levels alone can’t explain who’s headed for trouble, something else might. Over the next three years, FPN, with the help of our donors, is funding the research to find out.
This $516,842 grant-funded study is tracking 140 Dutch and 70 international patients’ blood over time, searching for early-warning proteins that might signal trouble before symptoms worsen. Once researchers identify likely candidates, they’ll test whether those same signals show up in patients from other IMAGiNe countries to see if the pattern holds beyond one country’s data.
This year, the search went from funded to underway. Dr. Perry van Doormaal at UMC Utrecht, one of the leading investigators of IMAGiNe, is working with Lisa Bos, a dedicated PhD researcher on his team, to map patient blood samples for the clues that might matter most. And the patients who make this possible keep showing up. Enrollment across the consortium has grown 15% in the past year, with researchers and clinical centers around the world contributing.
Real progress looks like this: not a breakthrough overnight, but a real step toward the answers patients and their doctors have needed for years. Every sample studied, every pattern validated, brings us closer to understanding this disease well enough to finally change what’s possible for the people living with it.
This is just the beginning of what’s possible with the backing and support of the FPN community. We won’t stop pushing to understand this disease better and to find the answers patients and doctors have been waiting for. Every patient living with peripheral neuropathy deserves a future built on real answers, not guesses.
